AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15701892 — intervention group
Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 330
Study 12500989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (60 g daily)
Number of subjects: 35
Study 12500989 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (60 g daily)
Number of subjects: 35
Study 11966624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 30 MU
Number of subjects: 115
Study 11966624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 50 MU
Number of subjects: 115
Study 11966624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 80 MU
Number of subjects: 115
Study 11966624 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (40 mg)
Number of subjects: 115
Study 11966624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (all doses)
Number of subjects: 115
Study 11966624 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 115
Study 9661606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal‐Glu GnRH antagonist (5, 15, 50, and 150 micrograms/kg)
Number of subjects: 11
Study 9661606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal‐Glu GnRH antagonist (150 micrograms/kg for 3-7 days)
Number of subjects: 11
Study 7514520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dansyl chloride labelling with surfactants and soap extracts (2% active ingredient, w/v)
Number of subjects: 0
Study 7514520 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactants and body cleansing products
Number of subjects: 0
Study 2622549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill's modified technique
Number of subjects: 132
Study 2622549 — intervention group
Group type: COMPARATOR
Intervention: Dor technique
Number of subjects: 132
Study 329940 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered closure with retention sutures
Number of subjects: 200
Study 329940 — intervention group
Group type: COMPARATOR
Intervention: Single-layer 'mass closure'
Number of subjects: 200
Study 6173843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 36
Study 6173843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30922358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention territories created using territory design software
Number of subjects: 24
Study 30922358 — intervention group
Group type: COMPARATOR
Intervention: Control territories created using territory design software
Number of subjects: 24
Study 29554849 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 361
Study 29554849 — intervention group
Group type: COMPARATOR
Intervention: Dose-equivalent usual occupational therapy (DEUCC)
Number of subjects: 361
Study 29554849 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (UCC)
Number of subjects: 361
Study 29554849 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 361
Study 27774458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 18
Study 27774458 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 18
Study 27774458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 18
Study 27774458 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 18
Study 24787632 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program for COPD patients
Number of subjects: 0
Study 24787632 — intervention group
Group type: COMPARATOR
Intervention: Control group of COPD patients not participating in the rehabilitation program
Number of subjects: 0
Study 24787632 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 22486843 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 24
Study 22486843 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 24
Study 20528593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 400 microg/day)
Number of subjects: 37
Study 20528593 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP; 400 microg/day)
Number of subjects: 37
Study 20528593 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 37
Study 18413638 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD) + RT
Number of subjects: 1554
Study 18413638 — intervention group
Group type: COMPARATOR
Intervention: Short-term ADT (STAD) + RT
Number of subjects: 1554
Study 18413638 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD) + RT (Gleason score 8-10)
Number of subjects: 1554
Study 18413638 — intervention group
Group type: COMPARATOR
Intervention: Short-term ADT (STAD) + RT (Gleason score 8-10)
Number of subjects: 1554
Study 15786853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed enrollees taking potentially contraindicated medications
Number of subjects: 406
Study 15786853 — intervention group
Group type: COMPARATOR
Intervention: Unexposed enrollees not taking potentially contraindicated medications
Number of subjects: 406
Study 14614228 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide treatment for 4 weeks
Number of subjects: 20
Study 14614228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 10673870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 211
Study 10673870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Sevoflurane
Number of subjects: 211
Study 10673870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 211
Study 9552519 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 516
Study 9552519 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 516
Study 1987737 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (Epi) 20 mg/m2 i.v. weekly
Number of subjects: 49
Study 1987737 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (Dox) 20 mg/m2 i.v. weekly
Number of subjects: 49
Study 6307941 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy (cyclophosphamide and CCNU)
Number of subjects: 271
Study 6307941 — intervention group
Group type: COMPARATOR
Intervention: Delayed chemotherapy (cyclophosphamide and CCNU)
Number of subjects: 271
Study 6307941 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation (TI), brain irradiation (BI), and early chemotherapy (CT)
Number of subjects: 271
Study 6307941 — intervention group
Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) alone
Number of subjects: 271
Study 6307941 — intervention group
Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) and chemotherapy (CT)
Number of subjects: 271
Study 6307941 — intervention group
Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) and brain irradiation (BI)
Number of subjects: 271
Study 6307941 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective brain irradiation
Number of subjects: 271
Study 31752566 — intervention group
Group type: EXPERIMENTAL
Intervention: Zal-SNEDDS
Number of subjects: 40
Study 29504254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol at 25,000 IU/wk
Number of subjects: 18
Study 29504254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27176725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen water (1000 mL/day)
Number of subjects: 178
Study 27176725 — intervention group
Group type: COMPARATOR
Intervention: Placebo water (normal water)
Number of subjects: 178
Study 24524674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling intervention
Number of subjects: 728
Study 24524674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 728
Study 22101215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study 22101215 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment
Number of subjects: 30
Study 20622677 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 < or =50/VL >100,000
Number of subjects: 2948
Study 20622677 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 < or =50/VL < or =100,000
Number of subjects: 2948
Study 20622677 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 51-200/VL >100,000
Number of subjects: 2948
Study 20622677 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 51-200/VL < or =100,000
Number of subjects: 2948
Study 17663611 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered intervention (Family Check-Up)
Number of subjects: 998
Study 17663611 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomized matched controls)
Number of subjects: 998
Study 15642301 — intervention group
Group type: EXPERIMENTAL
Intervention: 'J' wire
Number of subjects: 50
Study 15642301 — intervention group
Group type: COMPARATOR
Intervention: Straight wire
Number of subjects: 50
Study 12271348 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 90
Study 12271348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (LP)
Number of subjects: 90
Study 12271348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch&Prime 3.0 (EP)
Number of subjects: 90
Study 10598708 — intervention group
Group type: EXPERIMENTAL
Intervention: Codman Hakim programmable shunt valve
Number of subjects: 377
Study 10598708 — intervention group
Group type: COMPARATOR
Intervention: Conventional valve system
Number of subjects: 377
Study 10598708 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 377
Study 9163011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered in the evening (Group A)
Number of subjects: 80
Study 9163011 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin administered in the morning (Group B)
Number of subjects: 80
Study 1937374 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 400 mg cimetidine daily for 10 days
Number of subjects: 100
Study 1937374 — intervention group
Group type: COMPARATOR
Intervention: 2 x 400 mg cimetidine daily for 28 days
Number of subjects: 100
Study 7023678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 gm/day initially, increased to 1.6 gm/day for those with less than 50% reduction in ulcer size after three weeks)
Number of subjects: 20
Study 7023678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet after lunch and one at bedtime)
Number of subjects: 20
Study 29268619 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide/dexamethasone (Pom/dex)
Number of subjects: 300
Study 29268619 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide/dexamethasone (Pom/dex) alone
Number of subjects: 300
Study 27355267 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44
Study 27355267 — intervention group
Group type: COMPARATOR
Intervention: Insulin (standard of care)
Number of subjects: 44
Study 23798044 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking VO(2max) test
Number of subjects: 12
Study 23798044 — intervention group
Group type: COMPARATOR
Intervention: Running VO(2max) test
Number of subjects: 12
Study 21126782 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat panel digital detector (FPDD) fluoroscopy
Number of subjects: 400
Study 20308671 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus docetaxel
Number of subjects: 1421
Study 20308671 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus TX (docetaxel + capecitabine)
Number of subjects: 1421
Study 20308671 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus T-X (docetaxel followed by capecitabine)
Number of subjects: 1421
Study 20308671 — intervention group
Group type: COMPARATOR
Intervention: EC plus TX
Number of subjects: 1421
Study 20308671 — intervention group
Group type: EXPERIMENTAL
Intervention: EC plus T-X
Number of subjects: 1421
Study 18535027 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised rehabilitation programme (treatment group, n = 49)
Number of subjects: 101
Study 18535027 — intervention group
Group type: COMPARATOR
Intervention: Control waitlist group (n = 52)
Number of subjects: 101
Study 15992459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 3 weeks)
Number of subjects: 422
Study 15992459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 12460864 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Urotensin II (UTN) levels in heart failure patients
Number of subjects: 126
Study 12460864 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N-terminal pro-brain natriuretic peptide (N-BNP) levels in heart failure patients
Number of subjects: 126
Study 12460864 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of HF using N-BNP
Number of subjects: 126
Study 12460864 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of HF using UTN
Number of subjects: 126
Study 12460864 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of NYHA class I HF using UTN
Number of subjects: 126
Study 12460864 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 126
Study 10731304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg) given 30 min or 3.5 hours before exertion
Number of subjects: 18
Study 10731304 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with Nedocromil sodium for 2 and 4 weeks
Number of subjects: 18
Study 7594444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan (100 mg twice a day)
Number of subjects: 16
Study 7594444 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice a day)
Number of subjects: 16
Study 7594444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Sinorphan and Captopril
Number of subjects: 16
Study 7594444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan alone or in combination with Captopril
Number of subjects: 16
Study 1940778 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation programme
Number of subjects: 305
Study 1940778 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 305
Study 7272867 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (one 4-I plasma exchange a month)
Number of subjects: 12
Study 7272867 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (Control)
Number of subjects: 12
Study 31990296 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C infusion
Number of subjects: 0
Study 31990296 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30099756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar puncture
Number of subjects: 35
Study 30099756 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based lumbar puncture
Number of subjects: 35
Study 27719107 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing form activity through the PLUNGE into Sport programme (9 training sessions of 30 min each)
Number of subjects: 90
Study 27719107 — intervention group
Group type: COMPARATOR
Intervention: 9-week wait-list control
Number of subjects: 90
Study 26332592 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (interactive website)
Number of subjects: 1150
Study 26332592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1150
Study 23453391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 12 weeks
Number of subjects: 50
Study 23453391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21425568 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Sophora Colon‐soluble Capsules (CSCC) plus Etiasa simulated placebo for 8 weeks
Number of subjects: 160
Study 21425568 — intervention group
Group type: COMPARATOR
Intervention: Etiasa plus CSCC simulated placebo for 8 weeks
Number of subjects: 160
Study 19251139 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 0
Study 19251139 — intervention group
Group type: COMPARATOR
Intervention: Microcoaxial phacoemulsification (microphaco)
Number of subjects: 0
Study 16882940 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (TC-Top) following carboplatin and paclitaxel
Number of subjects: 1308
Study 16882940 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (TC) following carboplatin and paclitaxel
Number of subjects: 1308
Study 16882940 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (TC-Top)
Number of subjects: 1308
Study 16882940 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (TC)
Number of subjects: 1308
Study 15554364 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetes patients
Number of subjects: 27
Study 15554364 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary males
Number of subjects: 27
Study 15554364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with BMI above 25 kg/m2
Number of subjects: 27
Study 15554364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with BMI below 25 kg/m2
Number of subjects: 27
Study 11730742 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg once daily)
Number of subjects: 201
Study 11730742 — intervention group
Group type: COMPARATOR
Intervention: IM progesterone (50 mg once daily)
Number of subjects: 201
Study 9164992 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50-200 mg, three times per day)
Number of subjects: 0
Study 9164992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 0
Study 8083699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg) capsules taken for 4 days before and 2 days after chemotherapy
Number of subjects: 223
Study 8083699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 2769131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 150
Study 2769131 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor cream
Number of subjects: 150
Study 2769131 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine cream
Number of subjects: 150
Study 239807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1.33 mg intramuscularly
Number of subjects: 3
Study 239807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg intramuscularly
Number of subjects: 3
Study 239807 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 50 mg
Number of subjects: 3
Study 239807 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 150 mg
Number of subjects: 3
Study 239807 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg intramuscularly
Number of subjects: 3
Study 31542745 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS HC invitation
Number of subjects: 366005
Study 25482145 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib with lenalidomide and dexamethasone
Number of subjects: 792
Study 25482145 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (control group)
Number of subjects: 792
Study 23193213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state (placebo)
Number of subjects: 6
Study 23193213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state (metreleptin)
Number of subjects: 6
Study 23193213 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet
Number of subjects: 6
Study 22069286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3 (Otelixizumab; ChAglyCD3)
Number of subjects: 12
Study 22069286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18308009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU; 80 mg twice daily)
Number of subjects: 22
Study 18308009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16572041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling with tampons
Number of subjects: 450
Study 16572041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling with vaginal swabs
Number of subjects: 450
Study 16572041 — intervention group
Group type: COMPARATOR
Intervention: Clinician sampling during speculum examination
Number of subjects: 450
Study 12679437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide therapy
Number of subjects: 0
Study 12679437 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0
Study 12679437 — intervention group
Group type: COMPARATOR
Intervention: Untreated diabetes
Number of subjects: 0
Study 11191009 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperamol (fixed combination of domperidone and paracetamol)
Number of subjects: 120
Study 11191009 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 120
Study 8772902 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 10 mg/kg
Number of subjects: 20
Study 8772902 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 5 mg/kg
Number of subjects: 20
Study 1993561 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil gel
Number of subjects: 168
Study 1993561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (younger than 35 years)
Number of subjects: 168
Study 6362343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 792
Study 6362343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 30825302 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training in the horizontal direction for 6 weeks
Number of subjects: 21
Study 30825302 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation for 30 min, 3 days per week for 6 weeks)
Number of subjects: 21
Study 30261084 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of ACEI therapy
Number of subjects: 275
Study 30261084 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ACEI therapy
Number of subjects: 275